Matching articles for "H pylori"
Naproxen/Esomeprazole (Vimovo)
The Medical Letter on Drugs and Therapeutics • September 20, 2010; (Issue 1347)
The FDA has approved the marketing of Vimovo
(AstraZeneca), a fixed-dose combination of the nonsteroidal
anti-inflammatory drug (NSAID) naproxen
and the proton pump inhibitor (PPI) esomeprazole,...
The FDA has approved the marketing of Vimovo
(AstraZeneca), a fixed-dose combination of the nonsteroidal
anti-inflammatory drug (NSAID) naproxen
and the proton pump inhibitor (PPI) esomeprazole, for
symptomatic relief of osteoarthritis, rheumatoid arthritis
and ankylosing spondylitis and to decrease the risk
of developing gastric ulcers in patients at risk for
NSAID-associated ulcers.
Primary Prevention of Ulcers in Patients Taking Aspirin or NSAIDs
The Medical Letter on Drugs and Therapeutics • March 8, 2010; (Issue 1333)
Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are common causes of peptic ulcer disease. Patients infected with Helicobacter pylori who take aspirin or another NSAID have an especially high...
Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are common causes of peptic ulcer disease. Patients infected with Helicobacter pylori who take aspirin or another NSAID have an especially high risk. Drugs that have been tried for prevention of ulcers in patients taking NSAIDs including H2-receptor antagonists, proton pump inhibitors (PPIs), aluminum- or magnesium-containing antacids, the prostaglandin misoprostol (Cytotec, and others), and antibiotics to eradicate H. pylori.
Click here to view the free full article.
Click here to view the free full article.